United Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of “Moderate Buy” from Brokerages

United Therapeutics Co. (NASDAQ:UTHR) has received an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $294.25.

A number of analysts recently issued reports on UTHR shares. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. SVB Leerink started coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target for the company. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Finally, Wells Fargo & Company lifted their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total transaction of $859,716.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $31,045.30. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,756.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total transaction of $859,716.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $31,045.30. The disclosure for this sale can be found here. Insiders sold a total of 136,990 shares of company stock worth $32,239,641 over the last 90 days. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics in the first quarter worth about $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics in the fourth quarter worth about $43,000. C M Bidwell & Associates Ltd. bought a new stake in United Therapeutics in the third quarter worth about $91,000. Janiczek Wealth Management LLC raised its position in United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Blue Trust Inc. raised its position in United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 46 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.9 %

UTHR opened at $233.85 on Wednesday. The firm has a market capitalization of $11.00 billion, a P/E ratio of 11.79 and a beta of 0.52. The firm’s 50 day moving average is $233.74 and its 200-day moving average is $228.76. United Therapeutics has a 52-week low of $204.44 and a 52-week high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.67 earnings per share. Analysts expect that United Therapeutics will post 23.45 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.